Academician
ÖMÜR GÖKMEN SEVİNDİK
PROFESÖR
DEMİROĞLU BİLİM ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Hematoloji (İç Hastalıkları)
Article counts come from two sources, each shown separately: YÖKSİS (academic declarations) and OpenAlex (open scholarly catalog). Patents and artistic activities are listed under the Works tabs below.
Index quartiles
Scopus (SJR)
49 Total
- Q1 9
- Q2 22
- Q3 15
- Q4 7
Other counts
- Excluding abstracts 44 Q1 6 Q2 20 Q3 15 Q4 7
- Best Q 49 Q1 9 Q2 22 Q3 12 Q4 6
- YÖKSİS rows 59 Q1 0 Q2 0 Q3 0 Q4 0
WoS (JCR)
48 Total
- Q1 7
- Q2 8
- Q3 19
- Q4 19
Other counts
- Excluding abstracts 43 Q1 4 Q2 7 Q3 17 Q4 19
- Best Q 48 Q1 7 Q2 8 Q3 18 Q4 15
- YÖKSİS rows 57 Q1 0 Q2 0 Q3 0 Q4 0
TR Index
17 articles
OpenAlex citation percentiles
Top 1% articles
0
Top 10% articles
2
Avg percentile
49.9%
Articles with percentile
65
OpenAlex citation percentile; covered works only (~52%).
What do these indicators mean?
- Q1–Q4: the quartile of the journal in the given index (Scopus/WoS). Q1 = top 25%, Q4 = bottom 25%.
- Top 1% / top 10%: number of works among the top 1% or 10% most-cited worldwide in the same field and year.
- Avg percentile: mean citation percentile of the works (100 = highest).
- Source: index quartiles from Scopus/WoS and TR Index flags; citation percentiles from OpenAlex.
Proceedings
Conference proceedings recorded in YÖKSİS.
Records
- 2020 CLL-395: Real-World Data from the Turkish National Chronic Lymphocytic Leukemia Registry
- 2017 Exchange transfüzyon uygulanan HIV ile koenfekte ağır P. falciparum sıtması: Olgu Sunumu
- 2017 Real-World Data in Relapsed Refractory Myeloma Patients Treated with Pomalidomide, a Multicenter Turkish Experience
- 2019 Artificial Intelligence to Assist Better Myeloma Care, is It the Time?
- Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic
- 2021 P-125: An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
- 2022 AKUT LÖSEMİ İLİŞKİLİ NADİR BİR DURUM: GATA BİNDİNG PROTEİN2 (GATA2) EKSİKLİĞİ
- Yeni Tanı Yaşlı AML hastalarında Azacitidin ve Decitabine İdamesinin Tedaviye Katkısı: Gerçek Yaşam Verisi
- Real-World Data in Relapsed Refractory Myeloma Patients Treated with Carfilzomib, a Multicenter Turkish Experience
- 2019 Turkish Acute Lymphoblastic Leukemia Registry, Retrospective Phase Data
- A Case Series of CML Patients Who Were Presented with Isolated Thrombocytosis
- 2019 YAŞAM SÜRESİNİ VE KALİTESİNİ ETKİLEYEN DİRENÇLİ KGVHH TEDAVİSİNDE YENİ BİR YAKLAŞIM;BTK İNHİBİTÖRÜ:GERÇEK YAŞAM VERİSİ
- Physicians Poster Sessions
- Türkiye’de terapötik Plazma Exchange Aktivitesi:Ulusal Araştırma
- 2020 YENİ TANI MULTİPLE MYELOM HASTALARINDA KEMİK İLİĞİ FİBROZİSİNİN PROGNOZ VE YANIT ÜZERİNE ETKİSİ VAR MIDIR?
- 2019 KIRK YAŞ VE ALTI GENÇ MULTİPLE MİYELOM HASTALARININ KLİNİKOPATOLOJİK ÖZELLİKLERİ: ÇOK MERKEZLİ KESİTSEL ÇALIŞMA
- Comparison of outcomes of total body irradiation (TBI) vs non-TBI conditioning regimens in acute lymphoblastic leukemia for allogeneic transplantation
- 2017 REAL WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH POMALIDOMIDE, A MULTICENTER TURKISH EXPERİENCE
- 2017 REAL WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH CARFILZOMIB, A MULTICENTER TURKISH EXPERİENCE
- 2017 REAL WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH CARFILZOMIB, A MULTICENTER EXPERİENCE